ASC fusion protein platform

Protein drugs can be administered through the bloodstream but face challenges in directly affecting target cells and penetrating the cell cytoplasm to exert their function.

 

Our company's developed fusion protein drug delivery platform (ASC platform) represents a protein drug with dual targeting through antibody-peptide binding, addressing both of the aforementioned issues. This antibody-peptide protein drug concentrates around target cells and avoids cellular endocytosis, allowing it to enter the cell, thus enabling targeted regulation of functional targets both inside and outside the cell.